Beam Therapeutics Inc. — Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is an early-stage biotechnology company developing precision genetic medicines based on base-editing and related delivery technologies. The filing covers the quarter and nine months ended September 30, 2023. Beam has not generated product revenue and remains dependent on license and collaboration revenue, equity financing, and future strategic transactions.
Key programs include BEAM-101 for sickle cell disease, BEAM-201 for relapsed or refractory T-cell acute lymphoblastic leukemia, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease type Ia. The company began operating its North Carolina manufacturing facility in early 2023 and initiated cGMP operations in late 2023.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| License and collaboration revenue | $17.2 million, versus $15.8 million | $61.5 million, versus $40.9 million |
| Research and development expense | $100.1 million, versus $85.3 million | $297.3 million, versus $225.3 million |
| General and administrative expense | $25.4 million, versus $21.8 million | $73.6 million, versus $65.1 million |
| Loss from operations | $108.3 million, versus $91.3 million | $309.3 million, versus $249.5 million |
| Net loss | $96.1 million, versus $109.6 million | $275.3 million, versus $250.7 million |
| Net loss per share | $1.22, versus $1.56 | $3.63, versus $3.59 |
| Operating cash flow | Not separately provided | $(284.3) million, versus $91.7 million provided |
Revenue growth was driven primarily by recognition under the Pfizer, Apellis, and Orbital collaborations. Nine-month operating expenses increased 27.7%, with higher external development, clinical, manufacturing, employee, facility, and stock-based compensation costs. The nine-month operating margin was approximately negative 503%, and the net margin was approximately negative 448%.
At September 30, 2023, cash and cash equivalents were $169.0 million, marketable securities were $846.4 million, and restricted cash was $8.7 million. Cash, cash equivalents, and marketable securities totaled approximately $1.0 billion. Total assets were $1.29 billion and stockholders’ equity was $778.9 million.
Total liabilities were $511.6 million. These included $285.7 million of lease liabilities, $1.4 million of equipment financing liabilities, and $278.1 million of deferred revenue. The filing does not identify material conventional funded debt. Aggregate future minimum commitments under office, laboratory, and equipment leases were $253.2 million, excluding certain operating costs.
Material changes versus the prior comparable period
- Nine-month collaboration revenue increased $20.6 million, or approximately 50%, to $61.5 million.
- Nine-month research and development expense increased $72.1 million, primarily from manufacturing and clinical expenses for BEAM-101 and BEAM-201, IND-enabling work for BEAM-301 and BEAM-302, and investment in lipid nanoparticle technology.
- Nine-month operating cash flow changed from $91.7 million provided in 2022 to $284.3 million used in 2023. The prior-year figure benefited from collection of Pfizer’s $300.0 million upfront payment.
- Beam raised $236.6 million net from common-stock offerings during the first nine months of 2023 and had issued 79.4 million shares at September 30, 2023, compared with 71.3 million at December 31, 2022.
- Net loss increased by $24.6 million for the first nine months, despite lower losses in the third quarter, because higher operating expenses outweighed increased collaboration revenue.
- Fair-value gains on success payment liabilities and Guide contingent consideration partly offset losses, while fair-value losses on Verve and Prime equity investments produced $17.9 million of expense for the nine-month period.
- Stock-based compensation increased to $76.0 million for the first nine months, compared with $61.8 million in 2022.
Guidance, outlook, commentary, risks, and unusual items
- Management expects cash, cash equivalents, and marketable securities at September 30, 2023 to fund operations and capital expenditures for at least the next 12 months. Management also states that additional financing will be required to support continuing operations and growth.
- Following an October 2023 portfolio prioritization and restructuring, Beam expects research and development expense to remain primarily unchanged over the next 12 months, as clinical-stage spending is offset by reductions in preclinical programs.
- The restructuring is expected to eliminate approximately 100 positions, or about 20% of the workforce, and incur approximately $6.6 million of one-time cash costs, primarily severance, in the fourth quarter of 2023.
- Beam expects to dose the first BEAM-101 patient by the end of 2023 and report data from multiple BEACON trial patients in 2024. The target enrollment is 45 treated patients.
- The company plans to submit a regulatory application for BEAM-302 outside the United States in the first quarter of 2024 and an IND for BEAM-301 in the first half of 2024. These are management expectations, not completed regulatory actions.
- Beam dosed the first BEAM-201 patient in August 2023 and expects to present first-cohort data by the end of 2024. It is focusing the program on T-cell acute lymphoblastic leukemia and seeking a partner for BEAM-201 and other ex vivo CAR-T programs.
- In October 2023, Eli Lilly acquired certain Verve-related rights for $200.0 million in cash, with potential additional development-stage payments of up to $350.0 million. Lilly also agreed to purchase approximately $50.0 million of Beam common stock at $24.94 per share. These transactions occurred after the balance-sheet date and are not included in September 30, 2023 liquidity.
- Beam accrued a $3.4 million liability related to allegations by a research institution involving confidentiality, trade-secret, and other claims concerning technology associated with BEAM-102 and BEAM-302. No complaint had been filed as of September 30, 2023, and the ultimate outcome could materially exceed the accrued amount.
- Material risks include clinical-trial delays or failures, patient enrollment challenges, regulatory uncertainty, dependence on third-party manufacturers and supplies, limited cGMP capacity, intellectual-property disputes, additional capital requirements, restructuring execution risk, and reliance on key personnel.
- Potential future obligations include up to $90.0 million of additional success payments to each of Harvard and the Broad Institute, plus up to $100.0 million of technology milestone payments and $220.0 million of product milestone payments under the Guide acquisition, generally payable in common stock.
Most important facts for an investor to verify
- Whether the Lilly transaction proceeds and approximately $50.0 million equity investment were received as expected and how they affect the company’s cash runway.
- Actual timing and results of BEAM-101 and BEAM-201 clinical development, including dosing, enrollment, safety, and efficacy data.
- Whether BEAM-302 and BEAM-301 regulatory submissions occur on the stated timelines and whether regulators authorize clinical trials.
- Actual restructuring costs, headcount reductions, program discontinuations, and resulting research and development savings.
- Cash burn, remaining ATM capacity, equity dilution, and the timing and terms of any additional financing.
- Resolution and potential exposure from the research institution’s trade-secret and confidentiality allegations.
- Intellectual-property rights and litigation exposure affecting base editing, CRISPR-related technology, delivery systems, and product candidates.
- Progress toward sustained cGMP operations and the company’s ability to secure reliable third-party manufacturing and non-human-primate supplies.